Medicus Pharma Ltd. Common Stock
MDCXHealthcare|Biotechnology|CA
$1.87
+0.04 (+2.19%)
DCF Value
$4.14
Cash / Share
$4.56
Financials
Financial Snapshot
Market Cap
$2.7M
Enterprise Value
-$2.2M
Revenue (TTM)
$0.00
Net Income (TTM)
-$39.1M
Cash & Investments
$5.0M
Net Cash
$4.9M
Free Cash Flow (TTM)
-$32.0M
Operating CF (TTM)
-$32.0M
Debt/Equity
-0.01
Cash Runway & Burn Rate
Cash on Hand
$5.0M
Quarterly Burn
$8.0M
Monthly Burn
$2.7M
Est. Runway
~0.6 quarters
| Metric | Trend | 2021 | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|---|---|
| Cash & Investments | $78.5K | $267.7K | $1.7M | $4.2M | $8.7M | $5.0M | |
| Operating Cash Flow | -$1.4M | -$1.1M | -$4.2M | -$10.2M | -$22.8M | -$32.0M | |
| Free Cash Flow | -$1.4M | -$1.1M | -$4.2M | -$10.2M | -$22.8M | -$32.0M | |
| Capital Expenditure | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | -$2.00 | |
| Financing Cash Flow | $882.4K | $1.2M | $5.6M | $12.7M | $31.9M | -$4.4M |
R&D Spending
R&D (TTM)
$20.6M
R&D Intensity
—
R&D Growth vs Prior
+166.9%
| Metric | Trend | 2021 | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|---|---|
| Revenue | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | |
| R&D Expense | $1.2M | $646.4K | $193.6K | $3.5M | $7.7M | $20.6M | |
| SG&A | $258.0K | $332.0K | $2.5M | $7.7M | $17.9M | $22.7M |
Income Statement
| Metric | Trend | 2021 | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|---|---|
| Revenue | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | |
| Cost of Revenue | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | |
| Gross Profit | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | |
| R&D | $1.2M | $646.4K | $193.6K | $3.5M | $7.7M | $20.6M | |
| SG&A | $258.0K | $332.0K | $2.5M | $7.7M | $17.9M | $22.7M | |
| Operating Income | -$1.4M | -$978.4K | -$4.7M | -$11.2M | -$18.4M | -$37.8M | |
| Interest Expense | $115.4K | $526.8K | $595.5K | $317.5K | $141.3K | -$30.5K | |
| Pretax Income | -$2.1M | -$1.7M | -$5.3M | -$11.2M | -$25.4M | -$39.2M | |
| Net Income | -$2.1M | -$1.7M | -$5.3M | -$11.2M | -$25.4M | -$39.1M | |
| EPS (Diluted) | -13.00 | -8.00 | -24.50 | -34.50 | -98.00 | -81.00 | |
| EBITDA | -$1.9M | -$1.2M | $1.8M | -$11.2M | -$25.2M | -$39.2M | |
| Shares Out. (M) | 0.16 | 0.16 | 0.16 | 0.24 | 0.35 | 1.10 |
Balance Sheet
| Metric | Trend | 2021 | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|---|---|
| Cash & Equivalents | $78.5K | $267.7K | $1.7M | $4.2M | $8.7M | $5.0M | |
| Short-Term Investments | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | |
| Total Current Assets | $78.5K | $282.7K | $1.9M | $5.4M | $9.9M | $6.4M | |
| Total Assets | $78.5K | $282.7K | $1.9M | $5.6M | $10.1M | $14.5M | |
| Total Current Liabilities | $10.6M | $12.5M | $781.6K | $2.3M | $9.9M | $9.7M | |
| Long-Term Debt | $0.00 | $0.00 | $0.00 | $0.00 | $18.9K | $0.00 | |
| Total Liabilities | $10.6M | $12.5M | $781.6K | $2.5M | $10.0M | $25.0M | |
| Stockholders' Equity | -$10.5M | -$12.2M | $1.1M | $3.1M | -$67.6K | -$10.5M | |
| Retained Earnings | -$10.7M | -$12.4M | -$17.7M | -$28.9M | -$64.3M | -$100.2M |
Cash Flow Statement
| Metric | Trend | 2021 | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|---|---|
| Operating Cash Flow | -$1.4M | -$1.1M | -$4.2M | -$10.2M | -$22.8M | -$32.0M | |
| Capital Expenditure | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | -$2.00 | |
| Free Cash Flow | -$1.4M | -$1.1M | -$4.2M | -$10.2M | -$22.8M | -$32.0M | |
| Investing Cash Flow | $0.00 | $0.00 | $0.00 | $0.00 | -$4.6M | $41.5K | |
| Financing Cash Flow | $882.4K | $1.2M | $5.6M | $12.7M | $31.9M | -$4.4M | |
| Issuance of Stock | $0.00 | $0.00 | $0.00 | $7.5M | $19.8M | $17.8M | |
| Repurchase of Stock | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | |
| Net Debt Issuance | $882.4K | $1.2M | $500.0K | $5.2M | $3.1M | $10.1M | |
| Stock Based Comp. | $0.00 | $0.00 | $98.6K | $713.1K | $1.5M | $1.5M | |
| Net Change in Cash | -$565.7K | $189.1K | $1.5M | $2.4M | $4.5M | $4.5M |
Dilution Tracker
Shares outstanding grew 114.7% over 5 years — significant dilution
Shares Outstanding
1M
5-Year Share Growth
+114.7%
Stock Issuance (TTM)
$17.8M
| Metric | Trend | 2021 | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|---|---|
| Shares Out. (M) | 0.16 | 0.16 | 0.16 | 0.24 | 0.35 | 1.10 | |
| Change vs Prior % | — | 0.3% | -0.0% | 46.3% | 46.3% | 218.5% | |
| Stock Issuance | $0.00 | $0.00 | $0.00 | $7.5M | $19.8M | $17.8M | |
| Stock Repurchase | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | |
| Stock Based Comp. | $0.00 | $0.00 | $98.6K | $713.1K | $1.5M | $1.5M |
Margins & Profitability
| Metric | Trend | 2021 | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|---|---|
| ROE % | 19.6% | 13.9% | -478.2% | -355.9% | 37549.8% | 1491.0% | |
| ROA % | -2617.7% | -598.8% | -280.8% | -197.6% | -252.1% | -269.3% | |
| ROIC % | 14.7% | 9.2% | -425.6% | -323.4% | -452.4% | -770.7% |
Growth (Year over Year)
Fiscal years. Rising share count growth means dilution.
| Metric | Trend | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|
| Revenue | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | |
| Gross Profit | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | |
| Operating Income | 0.0% | 32.1% | -383.4% | -136.4% | -64.1% | |
| Net Income | 0.0% | 17.7% | -214.0% | -109.9% | -127.4% | |
| EPS (Diluted) | 0.0% | 38.5% | -206.3% | -40.8% | -184.1% | |
| Operating Cash Flow | 0.0% | 27.0% | -293.4% | -146.4% | -122.3% | |
| Free Cash Flow | 0.0% | 27.0% | -293.4% | -146.4% | -122.3% | |
| R&D Expense | 0.0% | -45.4% | -70.1% | 1722.4% | 118.9% | |
| SG&A Expense | 0.0% | 28.7% | 642.3% | 210.5% | 134.2% | |
| Total Assets | 0.0% | 260.0% | 569.7% | 198.3% | 78.2% | |
| Book Value / Share | 0.0% | -15.7% | 109.1% | 92.8% | -99.2% | |
| Debt | 0.0% | 129.3% | -100.0% | 0.0% | 1139.8% | |
| Diluted Shares | 0.0% | 0.3% | -0.0% | 46.3% | 46.3% |
Valuation
P/E (TTM)At Loss
P/S0.00
P/B-0.20
EV/EBITDA0.06
EV/Revenue0.00
P/FCFAt Loss
Intrinsic Value Models (per share)
DCF Value
$4.14
Cash / Share
$4.56
| Metric | Trend | 2021 | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|---|---|
| P/E Ratio | -10.19 | -16.56 | -5.41 | -3.52 | -0.78 | -0.02 | |
| P/S Ratio | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| P/B Ratio | -2.03 | -1.75 | 19.26 | 9.16 | -391.45 | -0.20 | |
| EV/EBITDA | -11.30 | -19.45 | 10.93 | -2.23 | -0.86 | 0.06 | |
| EV/Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Analyst Estimates & Quality
Altman Z-Score
-18.77
Distress
Piotroski F-Score
2
Weak
Forward Estimates (consensus)
| Metric | FY2026 | FY2027 | FY2028 |
|---|---|---|---|
| Revenue | $49.4K | $0.00 | $31.3M |
| Net Income | -$11.4M | -$6.1M | -$5.2M |
| EPS | $-33.05 | $-17.58 | $-15.53 |
| # Analysts (EPS) | 2 | 2 | 3 |